About
Tallac Therapeutics™ is a privately held clinical stage biopharmaceutical company based in the San Francisco Bay Area. Our multi-disciplinary team is rapidly advancing company’s lead oncology programs in multiple indications. Tallac’s pipeline of oligonucleotide-based ADC candidates includes novel Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to systemically deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) and trigger immune activation within the tumor microenvironment. Several TRAAC molecules are in various stages of discovery and development, including two programs in the clinic.
Tallac team
![](https://www.tallactherapeutics.com/wp-content/uploads/2021/10/thumb_-Stacy-Fide.jpg)
Stacy Fide
Associate Director,
Study Management
![](https://www.tallactherapeutics.com/wp-content/uploads/2021/03/thumb_Ons-Harrabi.jpg)
Ons Harrabi
Associate Director,
Clinical Biomarkers
![](https://www.tallactherapeutics.com/wp-content/uploads/2021/03/thumb_Maja-Bonarcosi.jpg)
Maja Bonacorsi
Principal Scientist
![](https://www.tallactherapeutics.com/wp-content/uploads/2020/11/thumb_Amy-Chen.jpg)
Amy Chen
Principal Scientist
![](https://www.tallactherapeutics.com/wp-content/uploads/2020/11/thumb_Emma-Sangalang.jpg)
Emma Sangalang
Principal Scientist
![](https://www.tallactherapeutics.com/wp-content/uploads/2022/05/thumb_Tiffany-Chou.jpg)
Tiffany Chou
Scientist
![](https://www.tallactherapeutics.com/wp-content/uploads/2020/11/thumb_Danielle-Fontaine.jpg)
Danielle Fontaine
Scientific Associate II
![](https://www.tallactherapeutics.com/wp-content/uploads/2021/04/thumb_-Verwina-Roble.jpg)
Verwina Roble
Sr. Accountant / Office Manager